Cobra's oral vacc platform supported in anthrax

Keele, UK-based Cobra Biomanufacturing and the UK's Defence Science and Technology Laboratory have conducted research showing that Cobra's oral  vaccination platform allows easy oral administration and cost effective  manufacture of a vaccine against anthrax.

The experiments, conducted at the DSTL and funded by Ploughshare  Innovations demonstrated that the Salmonella-based oral ORT-VAC vaccines  containing stable plasmids expressing a vaccine antigen offered  significantly greater protection in mice against a lethal strain of  anthrax, compared to the alternative approach of placing the vaccine  gene on the bacterial chromosome.

According to Cobra, ORT-VAC enables a higher vaccine dose to be  delivered. The study data were recently published in the journal  Microbial Pathogenesis.